Test it earlier, result it faster, makes us stronger: how rapid viral diagnostics enable therapeutic success.
Curr Opin Virol
; 49: 111-116, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1260705
ABSTRACT
The COVID-19 pandemic has entailed simultaneous revolutions in virology diagnostics, clinical trials management, and antiviral therapy and vaccinology. Over the past year, SARS-CoV-2 diagnostic testing has moved from highly centralized laboratories to at-home and even over the-counter. This transition has been lionized for its potential public health impact via isolation, but has been less examined for its effect on individual health and therapeutics. Since early initiation of antiviral therapy routinely has been associated with greater treatment efficacy for viral infections, these diagnostic testing innovations offer new opportunities for both clinical testing as well as clinical trials for antiviral therapy. Given a rapidly growing antiviral therapeutic pipeline and the profound impact of individual beneficiary outcomes on sculpting reimbursement policy, the therapeutic benefits associated with rapid viral testing may lead to significant adoption beyond potential public health impacts.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Point-of-Care Testing
/
COVID-19 Testing
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Curr Opin Virol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS